Trzonkowski Piotr, Zilvetti Miguel, Friend Peter, Wood Kathryn J
Transplantation Research Immunology Group and Oxford Transplant Centre, Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom.
Transplantation. 2006 Nov 27;82(10):1342-51. doi: 10.1097/01.tp.0000239268.64408.84.
Treatment with CAMPATH-1H at the time of transplantation allows reduced maintenance immunosuppression. We hypothesized that CAMPATH-1H induction would modulate the response of repopulating leukocytes to donor alloantigens.
The phenotype, proliferative and stimulatory capacity of peripheral blood leukocytes from 14 renal transplant recipients treated with CAMPATH-1H and reduced immunosuppression with mycophenolate mofetil and tacrolimus were investigated for the first six months after transplantation. The impact of immunosuppressive drugs on leukocytes that escape depletion was also evaluated in vitro.
CAMPATH-1H therapy caused a significant decrease in the number of B and T cells, with CD4 T central memory cells being the most resistant to depletion. The recovery of CD8 T cells was faster than that of CD4 T cells. Lymphopenia correlated with a decrease in both proliferative and effector responses, however, the recipient T cells remained responsive to third-party antigens. Dendritic cells (DC) were also depleted but to a lesser extent than lymphocytes; lymphoid DC were more resistant than myeloid DC; these changes correlated with decreased allostimulatory capacity. One of the patients experienced rejection that was treated successfully. The rejection was associated with a high proportion of CD4 T effector memory cells and myeloid DC, increased proliferation and enhanced effector activity to donor antigens. In vitro studies confirmed that the reduced dose of immunosuppressive drugs used could prevent activated T cells from switching to the effector compartment, suppressing both their proliferation and effector activity.
CAMPATH-1H induction combined with reduced maintenance immunosuppression is sufficient to control the effector phase of immune response to donor antigens.
在移植时使用CAMPATH-1H可减少维持性免疫抑制。我们推测CAMPATH-1H诱导会调节再填充白细胞对供体同种异体抗原的反应。
对14例接受CAMPATH-1H治疗并使用霉酚酸酯和他克莫司降低免疫抑制的肾移植受者,在移植后的前六个月研究其外周血白细胞的表型、增殖和刺激能力。还在体外评估了免疫抑制药物对未被清除的白细胞的影响。
CAMPATH-1H治疗导致B细胞和T细胞数量显著减少,其中CD4 T中央记忆细胞对清除最具抗性。CD8 T细胞的恢复比CD4 T细胞更快。淋巴细胞减少与增殖反应和效应反应的降低相关,然而,受者T细胞对第三方抗原仍有反应。树突状细胞(DC)也被清除,但程度低于淋巴细胞;淋巴样DC比髓样DC更具抗性;这些变化与同种异体刺激能力降低相关。其中一名患者发生了排斥反应,但成功得到治疗。该排斥反应与高比例的CD4 T效应记忆细胞和髓样DC、增殖增加以及对供体抗原的效应活性增强有关。体外研究证实,所使用的免疫抑制药物剂量减少可阻止活化的T细胞转变为效应细胞亚群,抑制其增殖和效应活性。
CAMPATH-1H诱导联合降低维持性免疫抑制足以控制对供体抗原的免疫反应效应阶段。